Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients myocardial infarction

David A. Ganz, Karen M. Kuntz, Gretchen A. Jacobson, Jerry Avorn

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Background: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy has proven efficacy in reducing the rate of coronary and cerebrovascular events in patients 75 years of age or younger with a history of myocardial infarction. However, in patients older than 75 years of age, the efficacy and potential cost-effectiveness of statins are unknown. Objective: To estimate the incremental cost-effectiveness of statin therapy compared with usual care in patients 75 to 84 years of age with previous myocardial infarction. Design: Cost-effectiveness analysis. Data Sources: Published data from cohort studies. Target: Population: Patients 75 to 84 years of age with a history of myocardial infarction. Time Horizon: Lifetime. Perspective: Societal. Intervention: Statin therapy. Outcome Measures: Life expectancy, quality-adjusted life expectancy, and incremental cost- effectiveness. Results of Base-Case Analysis: The incremental cost- effectiveness of statin therapy compared with usual care in patients 75 to 84 years of age with previous myocardial infarction was $18 800 per quality- adjusted life-year (QALY). Results of Sensitivity Analysis: On the basis of a probabilistic sensitivity analysis, there is a 75% chance that statin therapy costs less than $39 800 per QALY compared with usual care. If the cost of statin therapy and efficacy of statin therapy at reducing myocardial infarction were set to their most favorable values, statin therapy cost $5400 per QALY; if cost and efficacy were set to their least favorable values, statin therapy cost $97 800 per QALY. Conclusions: The cost-effectiveness ratios of statin therapy in older patients with previous myocardial infarction are reasonable under a wide variety of assumptions about drug efficacy, drug cost, and rates of cardiac and cerebrovascular events. Pending results of randomized, controlled trials of secondary prevention in patients in this age group, statin therapy seems to be as cost-effective as many routinely accepted medical interventions in this setting.

Original languageEnglish (US)
Pages (from-to)780-787
Number of pages8
JournalAnnals of Internal Medicine
Volume132
Issue number10
DOIs
StatePublished - May 16 2000

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cost-Benefit Analysis
Oxidoreductases
Myocardial Infarction
Quality-Adjusted Life Years
Costs and Cost Analysis
Therapeutics
Life Expectancy
3-hydroxy-3-methylglutaryl-coenzyme A
Patient Care
Quality of Life
Drug Costs
Health Services Needs and Demand
Information Storage and Retrieval
Group Psychotherapy
Secondary Prevention
Cohort Studies

Cite this

Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients myocardial infarction. / Ganz, David A.; Kuntz, Karen M.; Jacobson, Gretchen A.; Avorn, Jerry.

In: Annals of Internal Medicine, Vol. 132, No. 10, 16.05.2000, p. 780-787.

Research output: Contribution to journalArticle

@article{1ab44d5b7ccb4a5e8e183a09e274898f,
title = "Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients myocardial infarction",
abstract = "Background: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy has proven efficacy in reducing the rate of coronary and cerebrovascular events in patients 75 years of age or younger with a history of myocardial infarction. However, in patients older than 75 years of age, the efficacy and potential cost-effectiveness of statins are unknown. Objective: To estimate the incremental cost-effectiveness of statin therapy compared with usual care in patients 75 to 84 years of age with previous myocardial infarction. Design: Cost-effectiveness analysis. Data Sources: Published data from cohort studies. Target: Population: Patients 75 to 84 years of age with a history of myocardial infarction. Time Horizon: Lifetime. Perspective: Societal. Intervention: Statin therapy. Outcome Measures: Life expectancy, quality-adjusted life expectancy, and incremental cost- effectiveness. Results of Base-Case Analysis: The incremental cost- effectiveness of statin therapy compared with usual care in patients 75 to 84 years of age with previous myocardial infarction was $18 800 per quality- adjusted life-year (QALY). Results of Sensitivity Analysis: On the basis of a probabilistic sensitivity analysis, there is a 75{\%} chance that statin therapy costs less than $39 800 per QALY compared with usual care. If the cost of statin therapy and efficacy of statin therapy at reducing myocardial infarction were set to their most favorable values, statin therapy cost $5400 per QALY; if cost and efficacy were set to their least favorable values, statin therapy cost $97 800 per QALY. Conclusions: The cost-effectiveness ratios of statin therapy in older patients with previous myocardial infarction are reasonable under a wide variety of assumptions about drug efficacy, drug cost, and rates of cardiac and cerebrovascular events. Pending results of randomized, controlled trials of secondary prevention in patients in this age group, statin therapy seems to be as cost-effective as many routinely accepted medical interventions in this setting.",
author = "Ganz, {David A.} and Kuntz, {Karen M.} and Jacobson, {Gretchen A.} and Jerry Avorn",
year = "2000",
month = "5",
day = "16",
doi = "10.7326/0003-4819-132-10-200005160-00003",
language = "English (US)",
volume = "132",
pages = "780--787",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "10",

}

TY - JOUR

T1 - Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients myocardial infarction

AU - Ganz, David A.

AU - Kuntz, Karen M.

AU - Jacobson, Gretchen A.

AU - Avorn, Jerry

PY - 2000/5/16

Y1 - 2000/5/16

N2 - Background: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy has proven efficacy in reducing the rate of coronary and cerebrovascular events in patients 75 years of age or younger with a history of myocardial infarction. However, in patients older than 75 years of age, the efficacy and potential cost-effectiveness of statins are unknown. Objective: To estimate the incremental cost-effectiveness of statin therapy compared with usual care in patients 75 to 84 years of age with previous myocardial infarction. Design: Cost-effectiveness analysis. Data Sources: Published data from cohort studies. Target: Population: Patients 75 to 84 years of age with a history of myocardial infarction. Time Horizon: Lifetime. Perspective: Societal. Intervention: Statin therapy. Outcome Measures: Life expectancy, quality-adjusted life expectancy, and incremental cost- effectiveness. Results of Base-Case Analysis: The incremental cost- effectiveness of statin therapy compared with usual care in patients 75 to 84 years of age with previous myocardial infarction was $18 800 per quality- adjusted life-year (QALY). Results of Sensitivity Analysis: On the basis of a probabilistic sensitivity analysis, there is a 75% chance that statin therapy costs less than $39 800 per QALY compared with usual care. If the cost of statin therapy and efficacy of statin therapy at reducing myocardial infarction were set to their most favorable values, statin therapy cost $5400 per QALY; if cost and efficacy were set to their least favorable values, statin therapy cost $97 800 per QALY. Conclusions: The cost-effectiveness ratios of statin therapy in older patients with previous myocardial infarction are reasonable under a wide variety of assumptions about drug efficacy, drug cost, and rates of cardiac and cerebrovascular events. Pending results of randomized, controlled trials of secondary prevention in patients in this age group, statin therapy seems to be as cost-effective as many routinely accepted medical interventions in this setting.

AB - Background: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy has proven efficacy in reducing the rate of coronary and cerebrovascular events in patients 75 years of age or younger with a history of myocardial infarction. However, in patients older than 75 years of age, the efficacy and potential cost-effectiveness of statins are unknown. Objective: To estimate the incremental cost-effectiveness of statin therapy compared with usual care in patients 75 to 84 years of age with previous myocardial infarction. Design: Cost-effectiveness analysis. Data Sources: Published data from cohort studies. Target: Population: Patients 75 to 84 years of age with a history of myocardial infarction. Time Horizon: Lifetime. Perspective: Societal. Intervention: Statin therapy. Outcome Measures: Life expectancy, quality-adjusted life expectancy, and incremental cost- effectiveness. Results of Base-Case Analysis: The incremental cost- effectiveness of statin therapy compared with usual care in patients 75 to 84 years of age with previous myocardial infarction was $18 800 per quality- adjusted life-year (QALY). Results of Sensitivity Analysis: On the basis of a probabilistic sensitivity analysis, there is a 75% chance that statin therapy costs less than $39 800 per QALY compared with usual care. If the cost of statin therapy and efficacy of statin therapy at reducing myocardial infarction were set to their most favorable values, statin therapy cost $5400 per QALY; if cost and efficacy were set to their least favorable values, statin therapy cost $97 800 per QALY. Conclusions: The cost-effectiveness ratios of statin therapy in older patients with previous myocardial infarction are reasonable under a wide variety of assumptions about drug efficacy, drug cost, and rates of cardiac and cerebrovascular events. Pending results of randomized, controlled trials of secondary prevention in patients in this age group, statin therapy seems to be as cost-effective as many routinely accepted medical interventions in this setting.

UR - http://www.scopus.com/inward/record.url?scp=0034673940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034673940&partnerID=8YFLogxK

U2 - 10.7326/0003-4819-132-10-200005160-00003

DO - 10.7326/0003-4819-132-10-200005160-00003

M3 - Article

VL - 132

SP - 780

EP - 787

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 10

ER -